The chance of getting HIV from a single encounter depends on the type of sex act, but it’s lower than most people assume. For the highest-risk sexual activity, receptive anal sex without a condom, the probability is about 1 in 72. For vaginal sex, the odds drop to roughly 1 in 1,250 for the receptive partner and 1 in 2,500 for the insertive partner. These numbers assume the other person is HIV-positive and not on treatment, with no condom or preventive medication involved.
Those baseline figures can shift significantly in either direction depending on biological factors like viral load, the presence of other infections, and whether prevention tools are in play.
Risk by Type of Sex Act
The CDC expresses HIV transmission risk as the number of infections expected per 10,000 exposures to an HIV-positive partner. Here’s how that breaks down for the major sexual routes:
- Receptive anal sex: 138 per 10,000 exposures, or about 1 in 72
- Insertive anal sex: 11 per 10,000 exposures, or about 1 in 909
- Receptive vaginal sex: 8 per 10,000 exposures, or about 1 in 1,250
- Insertive vaginal sex: 4 per 10,000 exposures, or about 1 in 2,500
- Oral sex (giving or receiving): Estimated between 0 and 4 per 10,000 exposures, classified as extremely low to negligible
These are averages across many studies and many people. They assume no condom use, no preventive medication, and an HIV-positive partner who is not on treatment. Your individual risk from a single encounter could be higher or lower depending on the factors below.
What Makes a Single Encounter Riskier
The most powerful factor is the HIV-positive partner’s viral load, which is the amount of virus circulating in their blood. During acute infection (the first few weeks after someone contracts HIV), viral load spikes dramatically. This stage increases the risk of transmission roughly sevenfold compared to the baseline numbers above. So receptive anal sex with someone in acute infection could carry a risk closer to 1 in 10 rather than 1 in 72.
Other factors that raise risk from any single encounter include having an existing sexually transmitted infection (especially one that causes open sores, like syphilis or herpes), tears or abrasions in the skin or mucous membranes, and bleeding during sex. These all create easier pathways for the virus to reach immune cells beneath the surface of the skin.
For insertive male partners, circumcision reduces the risk of female-to-male transmission by approximately 60%. The inner foreskin contains a high density of the immune cells HIV targets, so removing it shrinks the vulnerable surface area.
What Makes a Single Encounter Safer
Two facts dramatically change the math. First, if the HIV-positive partner is on treatment and has an undetectable viral load, the risk of sexual transmission drops to zero. This principle, known as Undetectable = Untransmittable (U=U), is backed by large studies tracking thousands of couples where one partner was HIV-positive with an undetectable viral load. Not a single sexual transmission occurred.
Second, PrEP (pre-exposure prophylaxis) reduces risk by about 92% when taken daily as prescribed. Efficacy drops with inconsistent use. In clinical trials, participants who took PrEP sporadically saw protection levels closer to 44%, while those with detectable drug levels in their blood achieved protection above 90%.
Condoms, when used correctly, reduce risk by a substantial margin as well. Combining condoms with PrEP or an undetectable viral load in the positive partner makes transmission from a single encounter extraordinarily unlikely.
How HIV Enters the Body
Understanding why risk varies by sex act helps put the numbers in context. HIV needs to reach specific immune cells that sit just beneath mucosal surfaces, the moist linings inside the rectum, vagina, and urethra. The virus can cross this barrier in a few ways: slipping through tiny breaks in the tissue, being carried across the lining by specialized immune cells, or directly fusing with immune cells it encounters at the surface.
The rectal lining is thinner and more fragile than vaginal tissue, which is why receptive anal sex carries the highest per-act risk. It’s also more prone to small tears during sex, giving the virus direct access to the bloodstream. The vaginal lining is thicker and more resilient, but it still contains the immune cells HIV targets. Once the virus infects even a small number of these cells locally, those infected cells migrate to nearby lymph nodes, where the virus begins replicating rapidly and spreads throughout the body.
This entire process is surprisingly inefficient. Less than 0.02% of virus particles that contact the mucosal surface actually make it through. That inefficiency is the reason per-act transmission rates are measured in single digits per 10,000 for most sexual exposures.
Symptoms After a Potential Exposure
About two-thirds of people who contract HIV develop flu-like symptoms within 2 to 4 weeks. This is called acute HIV infection, and it can include fever, sore throat, swollen lymph nodes, rash, muscle aches, and fatigue. These symptoms overlap with dozens of common illnesses, so you can’t diagnose HIV based on how you feel. The remaining third of newly infected people have no noticeable symptoms at all during this stage.
Symptoms, or lack of them, are not a reliable way to assess whether transmission occurred. Testing is the only way to know.
When and How to Get Tested
No HIV test can detect the virus immediately after exposure. Each type of test has a window period, the gap between when infection occurs and when the test can pick it up.
- Nucleic acid tests (NAT): Detect the virus itself in the blood. Window period is 10 to 33 days after exposure. This is the earliest a test can give a reliable result.
- Antigen/antibody combination tests (blood draw): Detect both viral proteins and the body’s immune response. Window period is 18 to 45 days.
- Antigen/antibody tests (finger prick): Same approach but slightly less sensitive. Window period is 18 to 90 days.
- Rapid antibody tests and home tests: Detect only antibodies. Window period is 23 to 90 days.
If you’re concerned about a specific encounter, a NAT test at around 2 to 3 weeks can provide early reassurance, but a negative result should be confirmed with a follow-up test after the full window period has passed. PEP (post-exposure prophylaxis) is a course of HIV medication that can prevent infection if started within 72 hours of exposure, with earlier initiation being more effective.